OertliKatalyst introduces vitreoretinal hand instruments

Article

Oertli has introduced OertliKatalyst, a new brand in conjunction with Katalyst.

Oertli has introduced OertliKatalyst, a new brand in conjunction with Katalyst.

OertliKatalyst consists of a new handpiece set, innovative tip geometrics, a choice of material and improved implementation of ergonomic basic principles. The brand has been developed from scratch and has resulted in numerous patent registrations.

Thomas Bosshard, Head of Marketing and Sales at Oertli, said, " We were looking for the right moment to launch and the right moment to bring the right combination of vitreo hand instruments. We looked at things like laser probes and forceps, scissors, polishers and so on. We wanted the right partner at the right moment and the right resources."

The retinal instruments were first launched at this year's ESCRS congress in Milan. CEO of Katalyst, Greg Scheller, commented, "They feature about 15 new tip designs that have not been previously available in the vitreoretinal market. We also have laser probes that have not yet been introduced in the world market. But they have in the US, as well as diamond membrane polishers. We will be introducing a continuous line of products as both companies move forward."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.